We are live on
!
Find out more
Caption Management Portfolio holdings
AUM
$21.5B
Turnover
58.11%
1-Year Est. Return
81.81%
This Fund
S&P 500
This Quarter
Est. Return
-0.74%
1 Year Est. Return
+81.81%
3 Year Est. Return
+226.72%
5 Year Est. Return
+294.21%
10 Year Est. Return
–
AUM
$17.1B
AUM Growth
+$2.54B
(+17%)
Cap. Flow
-$40.7M
Cap. Flow
% of AUM
-0.24%
Top 10 Holdings %
Top 10 Hldgs %
21.61%
Holding
2,194
New
682
Increased
333
Reduced
357
Closed
710
Avg Time Held Equity + Options
0.4
years
Top 10 Avg Time Held Equity + Options
0.2
years
Top 20 Avg Time Held Equity + Options
0.1
years
Avg Time Held Equity only
0.4
years
Top 10 Avg Time Held Equity only
0.3
years
Top 20 Avg Time Held Equity only
0.2
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Blue Owl Capital
OWL
|
+$166M |
| 2 |
Meta Platforms (Facebook)
META
|
+$72.1M |
| 3 |
NVIDIA
NVDA
|
+$63.6M |
| 4 |
Take-Two Interactive
TTWO
|
+$56.8M |
| 5 |
Global X Cybersecurity ETF
BUG
|
+$23.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$128M |
| 2 |
Alphabet (Google) Class C
GOOG
|
+$124M |
| 3 |
Netflix
NFLX
|
+$48.3M |
| 4 |
Microsoft
MSFT
|
+$33M |
| 5 |
Bristol-Myers Squibb
BMY
|
+$31.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 88.8% |
| 2 | Technology | 2.44% |
| 3 | Healthcare | 2.37% |
| 4 | Consumer Discretionary | 1.9% |
| 5 | Financials | 1.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1451
Gossamer Bio
GOSS
$54.4M
| $23.4K | ﹤0.01% |
891
-51
| -5% | -$6.41K |
2025 Q4
1 quarter
|
|
1452
CALL
Neumora Therapeutics
NMRA
$80.2M
| $23.4K | ﹤0.01% |
+12,000
| New | +$31.1K |
2026 Q1
0 quarters
|
|
1453
Wealthfront Corp
WLTH
$1.75B
| $23.1K | ﹤0.01% |
+2,500
| New | +$22.9K |
2026 Q1
0 quarters
|
|
1454
Abeona Therapeutics
ABEO
$266M
| $21.8K | ﹤0.01% |
4,874
-52,157
| -91% | -$261K |
2025 Q4
1 quarter
|
|
1455
Mereo BioPharma
MREO
$49.4M
| $21.1K | ﹤0.01% |
64,064
+14,064
| +28% | +$6.04K |
2025 Q1
4 quarters
|
|
1456
Janux Therapeutics
JANX
$1.06B
| $20.7K | ﹤0.01% |
1,488
-271,012
| -99% | -$3.72M |
2024 Q4
5 quarters
|
|
1457
DELISTED
OppFi Inc Warrants
OPFI.WS
| $18.1K | ﹤0.01% |
139,522
| – | – |
2025 Q2
3 quarters
|
|
1458
Mondelez International
MDLZ
$80.4B
| $17.3K | ﹤0.01% |
300
-61,300
| -100% | -$3.55M |
2025 Q2
3 quarters
|
|
|
1459
CALL
Gossamer Bio
GOSS
$54.4M
| $16.4K | ﹤0.01% |
625
+109
| +21% | +$13.7K |
2025 Q1
4 quarters
|
|
1460
First Horizon
FHN
$10.8B
| $15.7K | ﹤0.01% |
688
-205,132
| -100% | -$4.91M |
2023 Q4
9 quarters
|
|
1461
Satellogic Inc Warrant
SATLW
$14.6M
| $15.2K | ﹤0.01% |
+12,672
| New | +$10.5K |
2026 Q1
0 quarters
|
|
1462
Fusemachines Inc Warrants
FUSEW
| $14.2K | ﹤0.01% |
+189,939
| New | +$17.7K |
2026 Q1
0 quarters
|
|
1463
Aurora Innovation Warrant
AUROW
$18.3M
| $13.6K | ﹤0.01% |
68,535
| – | – |
2025 Q1
4 quarters
|
|
1464
Teladoc Health
TDOC
$1.08B
| $13.3K | ﹤0.01% |
2,439
-5,160
| -68% | -$29K |
2025 Q3
2 quarters
|
|
1465
DELISTED
Palladyne AI Corp Warrants
PDYNW
| $12.8K | ﹤0.01% |
178,604
| – | – |
2025 Q3
2 quarters
|
|
1466
Enovis
ENOV
$1.12B
| $8.53K | ﹤0.01% |
+375
| New | +$8.87K |
2026 Q1
0 quarters
|
|
1467
VistaGen Therapeutics
VTGN
$9.45M
| $8.38K | ﹤0.01% |
14,664
-2,106
| -13% | -$1.28K |
2025 Q4
1 quarter
|
|
1468
ImmunityBio
IBRX
$10.6B
| $7.67K | ﹤0.01% |
+1,000
| New | +$6.85K |
2026 Q1
0 quarters
|
|
1469
American Express
AXP
$212B
| $7.26K | ﹤0.01% |
+24
| New | +$8.05K |
2026 Q1
0 quarters
|
|
1470
Horizon Quantum Holdings Warrant
HQWWW
$45.1M
| $6.14K | ﹤0.01% |
+2,997
| New | +$7.13K |
2026 Q1
0 quarters
|
|
1471
Magnera Corp
MAGN
$401M
| $5.43K | ﹤0.01% |
571
-8,805
| -94% | -$113K |
2025 Q3
2 quarters
|
|
1472
Algoma Steel Group Warrant
ASTLW
$19.3K
| $4.43K | ﹤0.01% |
44,550
| – | – |
2025 Q3
2 quarters
|
|
1473
HDFC Bank
HDB
$121B
| $4.38K | ﹤0.01% |
+176
| New | +$5.47K |
2026 Q1
0 quarters
|
|
1474
Alphatec Holdings
ATEC
$1.69B
| $3.26K | ﹤0.01% |
+300
| New | +$4.37K |
2026 Q1
0 quarters
|
|
1475
Global X Uranium ETF
URA
$5.1B
| $2.33K | ﹤0.01% |
48
-40,499
| -100% | -$2.11M |
2025 Q3
2 quarters
|
|
Similar funds
Caption Management's Q1 2026 Portfolio in Review
As of Q1 2026, Caption Management held 2,194 positions worth $17.1B, up 17% from $14.6B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Caption Management's Q1 2026 filing shows 682 new, 333 increased, 357 reduced and 710 closed positions. Its largest new stake was Meta Platforms (Facebook): 112,500 shares worth $64.4M. The largest sale was Apple, an estimated $128M.
By sector, the portfolio is most concentrated in Miscellaneous at 89% of assets, up from 85% a quarter earlier, followed by Technology and Healthcare.
- Caption Management's largest Q1 2026 buy was Meta Platforms (Facebook): 112,500 shares worth $64.4M.
- Caption Management added most to Blue Owl Capital in Q1 2026, an estimated $166M increase.
- Caption Management's biggest Q1 2026 reduction was Alphabet (Google) Class C, cutting an estimated $124M.
- Caption Management fully exited Apple in Q1 2026, selling an estimated $128M.
- Caption Management's ten largest holdings make up 22% of its $17.1B portfolio in Q1 2026.
- Caption Management opened 682 new positions and closed 710 in Q1 2026.
- Caption Management's portfolio value rose 17% quarter-over-quarter to $17.1B.
Based on Caption Management's 13F filing for Q1 2026, filed 15 May 2026.